Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Mol Cancer Ther. 2009 Oct 27;8(11):3009–3014. doi: 10.1158/1535-7163.MCT-09-0470

Figure 3.

Figure 3

Susceptibility of NCI60 human cancer cell lines to treatment with IGFBP7 or a MEK inhibitor. A, Cell lines were treated with 10 μg rIGFBP7 for 24 hrs and analyzed for apoptosis by annexin V staining. B, Cell lines were treated with U0126 (10 μM) for 24 hrs and analyzed for proliferation by trypan blue exclusion. All experiments were performed in triplicate. Error bars represent SEM.